Abstract
BackgroundWe investigated the clinical outcome in patients whose cavitary bone defects were treated with beta-tricalcium phosphate (β-TCP) after surgical removal of benign tumors.MethodsBetween March 2015 and December 2015, 20 patients who underwent operation for bone tumors were enrolled into this study and prospectively followed up for a median period of 28.1 months.ResultsWhen the radiographic sign of complete resorption was defined as greater than 50% resorption of the allograft material accompanied by bone remodeling until 12 months, 55% of patients had complete resorption. Positive correlation between the filling volume and time needed for complete resorption was not found (p = 0.184).ConclusionsPurified β-TCP could be a suitable choice as a bone graft substitute after the removal of benign bone tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
